Table 1.
HLA class I and II surface expression in melanoma cell lines from ESTDAB
| Cell lines | HLA CLASS II | HLA class I | Phenotype | |||||
|---|---|---|---|---|---|---|---|---|
| Basal | IFN-γ | Basal | ||||||
| DR | DP | DQ | DR | DP | DQ | ABC | ||
| Group a (28.5%) | ||||||||
| ESTDAB-038 | – | – | – | – | – | – | – | Phenotype Iab |
| ESTDAB-109 | – | – | – | – | – | – | – | Phenotype Iab |
| ESTDAB-127 | – | – | – | – | – | – | + | Phenotype Ib |
| ESTDAB-094 | – | – | – | – | – | – | + | Phenotype Ib |
| ESTDAB-102 | – | – | – | – | – | – | + | Phenotype Ib |
| ESTDAB-081 | – | – | – | – | – | – | ± | Phenotype V |
| ESTDAB-195 | – | – | – | – | – | – | + | Phenotype V |
| ESTDAB-004 | – | – | – | – | – | – | + | Phenotype VIb |
| ESTDAB-159 | – | – | – | – | – | – | + | Phenotype VIb |
| ESTDAB-048 | – | – | – | – | – | – | ++ | Phenotype IIIa |
| ESTDAB-179 | – | – | – | – | – | – | ++ | Phenotype II |
| ESTDAB-049 | – | – | – | – | – | – | + | Phenotype IIIa |
| Group b (28.5%) | ||||||||
| ESTDAB-140 | – | – | – | + | – | – | + | Phenotype Ib |
| ESTDAB-073 | – | – | – | + | – | – | + | Phenotype Ib |
| ESTDAB-196 | – | – | – | + | + | – | + | Phenotype Ib |
| ESTDAB-020 | – | – | – | + | + | – | + | Phenotype Ib |
| ESTDAB-200 | – | – | – | + | + | – | ++ | Phenotype IIIa |
| ESTDAB-199 | – | – | – | + | + | – | ++ | Phenotype IIIa |
| ESTDAB-084 | – | – | – | + | + | – | +++ | Phenotype IIIa |
| ESTDAB-110 | – | – | – | + | + | – | ++ | No alterations detected |
| ESTDAB-112 | – | – | – | + | + | – | ++ | No alterations detected |
| ESTDAB-146 | – | – | – | + | + | – | +++ | No alterations detected |
| ESTDAB-069 | – | – | – | + | + | – | ||
| ESTDAB-162 | – | – | – | + | + | + | + | Phenotype V |
| Group c (24%) | ||||||||
| ESTDAB-070 | – | + | – | + | ++ | – | ++ | Phenotype II |
| ESTDAB-133 | – | + | – | + | ++ | – | ++ | Phenotype II |
| ESTDAB-071 | + | + | – | ++ | ++ | – | ++ | Phenotype II |
| ESTDAB-041 | + | + | – | ++ | ++ | – | ++ | Phenotype II |
| ESTDAB-058 | + | + | – | ++ | ++ | – | ++ | Phenotype II |
| ESTDAB-206 | + | + | – | ++ | ++ | – | ++ | Phenotype IIIa |
| ESTDAB-074 | + | + | – | ++ | ++ | – | ++ | Phenotype IIIa |
| ESTDAB-184 | + | + | – | ++ | ++ | – | +++ | No alterations detected |
| ESTDAB-153 | + | + | – | ++ | ++ | – | +++ | No alterations detected |
| ESTDAB-129 | + | + | – | ++ | ++ | ++ | ++ | Phenotype II |
| Group d (19%) | ||||||||
| ESTDAB-137 | + | + | + | + | ++ | ++ | + | Phenotype V |
| ESTDAB-167 | + | + | + | ++ | ++ | ++ | +++ | Phenotype II |
| ESTDAB-130 | + | + | + | ++ | ++ | ++ | +++ | Phenotype II |
| ESTDAB-108 | + | + | + | ++ | ++ | ++ | +++ | Phenotype IIIa |
| ESTDAB-152 | + | + | + | ++ | ++ | ++ | +++ | Phenotype IIIa |
| ESTDAB-183 | + | + | + | ++ | ++ | ++ | ++ | Phenotype IIIa |
| ESTDAB-016 | + | + | + | ++ | ++ | ++ | +++ | No alterations detected |
| ESTDAB-136 | + | + | + | ++ | ++ | ++ | +++ | No alterations detected |
aHLA-B downregulation
bNo response to IFN-γ treatment